Based on the role of MCPIP1 as a positive regulator inhibiting the IL6/JAK2/STAT3 axis, we propose that its expression may help identify patient subgroups with high IL6/JAK2/STAT3 axis activity (i.e., pancreatic cancer patients with strong metastatic potential). Here, JAK2 is linked to pancreatic neoplasm.